Publications by authors named "Misa Kamigaito"
Aim There are few reports on the prognostic factors associated with mortality in coronavirus disease (COVID-19) patients with critical disease. This study assessed prognostic factors associated with mortality of patients with critical COVID-19 who required ventilator management. Methods This single-center, retrospective cohort study used medical record data of COVID-19 patients admitted to an emergency ICU at a hospital in Japan between March 1, 2020 and September 30, 2021, and provided with ventilator management.
View Article and Find Full Text PDFArticle Synopsis
- This study explored whether tocilizumab, used to treat COVID-19, affects the likelihood of bacteremia and impacts fever and inflammation levels in patients.
- Conducted from March 2020 to August 2021, the research analyzed the health outcomes of 144 patients, splitting them into those treated with tocilizumab and those who were not.
- The findings showed that while tocilizumab treatment lowered C-reactive protein levels, indicating reduced inflammation, it did not increase bacteremia risk or significantly affect fever, suggesting the need for careful fever monitoring in patients.
Article Synopsis
- The study investigated the effects of tocilizumab, a treatment for COVID-19, on the incidence of bacteremia as well as its impact on fever and inflammatory markers in patients.
- It involved 144 patients, finding that 13 out of 24 with bacteremia had received tocilizumab, but the treatment did not significantly increase bacteremia risk or reduce fever.
- The conclusion suggests that while tocilizumab lowers C-reactive protein levels, it does not heighten bacteremia risk, indicating the need for monitoring fever to avoid overlooking potential infections.